ideology-health
  • Our Solutions
  • About Us
  • Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

    Published 2 days ago


    J

    John Mascarenhas, MD

    Medical Professional


    Recognizing HU Resistance: When to Switch

    Related Videos
    Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

    Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

    John Mascarenhas, MD
    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Rahul Banerjee, MD
    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Wade Iams, MD
    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.